Back to list

Health Economic Data

2013

  • Short and long-term cost-effectiveness of switching therapy from NPH insulin to insulin detemir in people with type 2 diabetes. PD Home et al.
    Key findings: Switching from NPH±OGLDs to detemir±OGLDs in people with T2DM as performed in the A1chieve® study was found to be cost-effective in both country settings at 1 and 30 year time horizons.
  • Short and long-term cost-effectiveness of switching therapy from insulin glargine to insulin detemir in people with type 2 diabetes R Malek et al.
    Key findings: Switching therapy from insulin glargine to insulin detemir in T2DM as performed in the A1chieve® study was found to be highly cost-effective across all country settings based on a 1 and 30-year time horizon. Sensitivity analyses showed the long-term costeffectiveness to be robust. Predicted life-expectancy increased and the relative risk of complications was reduced across all country settings based on a 30-year time horizon.
  • Short and long-term cost-effectiveness of initiating biphasic insulin aspart 30 in insulin-naive people with type 2 diabetes. PD Home et al.
    Key findings: Initiating biphasic insulin aspart 30 in insulin-naive people in Saudi Arabia, India, Indonesia and Malaysia was found to be cost effective over both a 1-year and a 30-year time horizon.
  • Short and long-term cost-effectiveness of switching therapy from biphasic human insulin 30 to biphasic insulin aspart 30 in people with type 2 diabetes. PD Home et al.
    Key findings: Switching from biphasic human insulin 30 ± OAD s to biphasic insulin aspart 30 ± OAD s was found to be cost-effective in India, Malaysia and Saudi Arabia at 1- and 30-year time horizons.
  • Short and long-term cost-effectiveness of switching therapy from insulin glargine to biphasic insulin aspart 30 in people with type 2 diabetes in Saudi Arabia and India. PD Home et al.
    Key findings: The switch from insulin glargine to biphasic insulin aspart 30 in Saudi Arabia and India was found to be less costly and have better outcomes over both a 1-year and a 30-year time horizon.
  • Short and long-term cost-effectiveness of initiating insulin detemir in insulin-naïve people with type 2 diabetes. PD Home et al.
    Key findings: Initiating insulin detemir in insulin-naïve people in Algeria, India, Indonesia, Malaysia, Mexico and South Korea was found to be cost effective over both a 1-year and a 30-year time horizon.
Back to list

Search this site

Insulin Management Programme

The Progress in Insulin Management Resource Centre is a global, online educational platform created to help healthcare professionals and diabetes specialists to optimize their management of patients with type 1 and type 2 diabetes. Its key features include a free, online educational program on insulin management (10 courses in 3 content areas), selected and commented articles, summaries, infographics, webcasts, interviews, and e-learning modules.

You can register for free, start as many courses as you want simultaneously and get a certificate after course completion.

A1chieve Resource Centre Expert Panel

  • Philip Home

    Professor Philip Home

    Philip Home is Professor of Diabetes Medicine at Newcastle University and consultant physician in Newcastle, UK. Professor Home is Chairman of A1chieve® Global Advisory Board.

    Read more »

A1chieve results from bangladesh and ASEAN countries

Now available in the Resource Centre, the just published supplement to Diabetes Research and Clin...

Read more »